Browse Studies — Arctuva

Phase 2

An Open-Label, Randomized, Multiple-Dose, Multi-Center Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of CTAP101 Extended-release Capsules in Pediatric Participants <18 Years of Age With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency

The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyr…

CKD Stage 3CKD Stage 4Secondary Hyperparathyroidism+1 more

Estimated

~$10 – $8,750

OPKO Health, Inc.NCT07494045

Precision Medicine Approaches to Renal Osteodystrophy

Treatment of renal osteodystrophy is impeded by the lack of practical and accurate tools to determine underlying bone turnover. Gold standard bone biopsy is no…

Renal OsteodystrophyChronic Kidney DiseasesCKD-MBD+2 more

Estimated

~$10 – $1,125

Thomas NickolasNCT05880914

A Phase 2 Biomarker Study of Parathyroid Tumor Clonal Status in Hyperparathyroid Disorders (Primary, Secondary, and Tertiary)

To define the frequency of monoclonal-X and polyclonal-X tumors in hyperparathyroid disorders patients having PTX and to define the relationship between parath…

Parathyroid TumorPrimary HyperparathyroidismSecondary Hyperparathyroidism (SHPT)+1 more

Estimated

~$10 – $750

Washington University School of MedicineNCT05997810

Phase 3

Phase 3, Randomized, Open-label, Controlled, Multiple Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 Days to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis

This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.

Secondary HyperparathyroidismChronic Kidney Disease

Estimated

~$10 – $7,500

AmgenNCT03633708